Aigen Investment Management, LP Mirati Therapeutics, Inc. Transaction History

Aigen Investment Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 02, 2022	SELL	$39.16 - $88.71 $176,807 - $400,525	-4,515 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$75.82 - $150.97 $81,582 - $162,443	1,076 Added 31.29%	4,515 $371,000
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $453,982 - $654,407	3,439 New	3,439 $483,000
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $542,393 - $728,432	-4,105 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$144.0 - $179.73 $323,712 - $404,033	-2,248 Reduced 35.38%	4,105 $663,000

Q1 2021 May 11, 2021	BUY	$158.92 - $221.61 $295,909 - $412,637	1,862 Added 41.46%	6,353 $1.09 Million
Q4 2020 Feb 12, 2021	SELL	$162.05 - $240.27 $281,642 - $417,589	-1,738 Reduced 27.9%	4,491 $986,000
Q3 2020 Nov 06, 2020	BUY	$113.26 - $167.27 $705,496 - $1.04 Million	6,229 New	6,229 $1.03 Million
Q1 2020 May 08, 2020	SELL	$69.78 - $116.21 $128,744 - $214,407	-1,845 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$70.76 - $128.86 $130,552 - $237,746	1,845 New	1,845 $238,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.